In multivariate analysis (including age, tumor stage, KRAS mutations, and NF1 alterations), KRAS mutations were strongly independently associated with a poor prognosis (P = 0.004, Hazard ratio, HR = 2.5), as well as KRAS and NF1 co‐mutations (P = 0.04, HR = 2.3) and advanced tumor stage (P < 0.0001, HR = 2.9; Table 3). Here, KRAS is linked to neoplasm.